Managed Care Thesis Faces Insider Selling Headwind; Merck Pipeline Advances Support Pharma Leg

Berkshire Hathaway and David Tepper both sold significant stakes in UnitedHealth in Q1 2026 despite bullish sell-side consensus, introducing a material contradiction to the managed-care thesis, while Merck's recent drug approvals and pipeline wins reinforce the pharma component.

What changed

Two major institutional investors executed large exits from UnitedHealth Group in the first quarter of 2026. Berkshire Hathaway and David Tepper's Appaloosa Management both reduced or eliminated their positions in the same quarter, according to 13F filings reported on June 22. This insider selling occurred while the sell-side consensus remained bullish: UnitedHealth carried 22 buy or strong-buy ratings with a consensus price target of $407.38, nearly matching the market price of $408.66 as of June 23.

On the pharma side, Merck reported positive clinical progress across multiple programs. The company announced that its drug tulisokibart met primary and key secondary endpoints in the Phase 3 ATLAS-UC induction-only study for moderately to severely active ulcerative colitis. Merck also won FDA expansions, posted HIV data, and ended a lung cancer trial. Additionally, Merck is deepening its kidney cancer franchise by combining KEYTRUDA and WELIREG, positioning these assets as a multi-indication growth engine.

J&J disclosed a strategic pivot away from the GLP-1 obesity drug race, instead targeting the number-one cancer spot by 2030. The company is also investing more than $1 billion to expand its Vision manufacturing, packaging, and distribution facilities in Jacksonville, Florida, as part of a broader $55 billion U.S. investment initiative in manufacturing and R&D.

UnitedHealth announced a proposed FTC settlement over insulin rebating practices, and the company is betting $3 billion on AI, claiming the technology is driving 2-to-1 returns and could cut operating costs by almost $1 billion this year.

Why it matters

Merck's pipeline advances and multi-indication expansion support the pharma leg of the thesis. The parent narrative states that Merck is attracting analyst upgrades and price target increases, with fair value models anchored well below current analyst targets. The tulisokibart Phase 3 win in ulcerative colitis, combined with the kidney cancer franchise deepening (KEYTRUDA + WELIREG), demonstrates that Merck is successfully expanding its oncology and immunology portfolios beyond single indications. This is the type of pipeline execution that historically justifies price-target increases and re-rating, because it extends the revenue runway and reduces patent-cliff risk. Each new indication approval or combination therapy win extends the commercial life of the asset and broadens the addressable patient population, which is the mechanism by which pharma companies move from single-drug dependency to diversified revenue streams.

J&J's strategic pivot away from GLP-1 and toward cancer is consistent with the thesis but raises execution risk. The thesis explicitly states it is "distinct from the GLP-1 drug coverage story already in the tree." J&J's decision to skip the GLP-1 race and target the number-one cancer spot by 2030 aligns with this framing—the thesis is not predicated on J&J winning in obesity drugs. However, the commitment to become a cancer leader by 2030 is a multi-year execution bet. The $1 billion Vision expansion and $55 billion U.S. investment initiative demonstrate capital deployment, but capital deployment alone does not guarantee market share gains or margin expansion. The thesis will depend on whether J&J's oncology pipeline can compete effectively against Merck, Roche, and other entrenched players.

UnitedHealth's AI investment and FTC settlement present mixed signals on operational momentum. The claim that AI is driving 2-to-1 returns and could cut operating costs by $1 billion annually is operationally bullish if realized, because it would improve the cost structure of the managed-care business and support margin expansion. However, the insulin rebating settlement introduces regulatory and reputational friction. Settlements often signal that prior practices were unsustainable or legally vulnerable, which can constrain future pricing power or negotiating leverage. The combination of these two signals—operational upside from AI, regulatory headwind from settlement—leaves the near-term trajectory for UnitedHealth unclear.

Opposing sources and risks

The insider selling by Berkshire Hathaway and David Tepper directly contradicts the bullish consensus on UnitedHealth. Both investors have long track records of disciplined capital allocation and patience with long-term theses; their simultaneous exit in Q1 2026 suggests they either (a) no longer believe the risk-reward justifies the position at current valuations, or (b) have identified near-term or medium-term headwinds that offset the long-term structural tailwinds cited in the thesis. The sell-side remained bullish at nearly the same price level, creating a notable divergence between insider and analyst sentiment.

J&J's decision to skip the GLP-1 race, while consistent with the thesis's distinction from the obesity-drug story, introduces execution risk. The company is betting on cancer as its number-one growth driver by 2030, but this is a multi-year, capital-intensive bet with no guarantee of market leadership. If J&J's oncology pipeline underperforms or faces competitive pressure, the thesis's confidence in J&J as a beneficiary of structural healthcare tailwinds would weaken.

The insulin rebating FTC settlement suggests that UnitedHealth's prior practices around drug-rebate negotiation may have been legally or ethically vulnerable. Settlements often constrain future behavior and can reduce pricing power or negotiating leverage, which would be a headwind to the managed-care thesis's assumption of margin expansion.

What to watch

UnitedHealth's next quarterly earnings and guidance. The insider selling and FTC settlement raise questions about near-term margin trajectory. Watch for management commentary on the AI cost-reduction initiative, the impact of the settlement on future rebate practices, and any revision to full-year earnings or margin guidance. If UnitedHealth guides down or misses on margins, the insider selling will be validated as prescient.

Merck's clinical pipeline readouts and approval cadence. The thesis assumes Merck's fair value is anchored below current analyst targets, implying upside from pipeline execution. Track the timing and outcomes of Phase 3 trials for tulisokibart (other indications), KEYTRUDA combinations, and other oncology assets. Each approval or positive readout should support analyst price-target increases; each setback would undermine the thesis.

J&J's oncology pipeline progress and competitive positioning. J&J has committed to becoming a cancer leader by 2030. Monitor clinical trial readouts, regulatory approvals, and market-share data for J&J's oncology franchises relative to Merck, Roche, and other competitors. If J&J gains share and achieves clinical wins, the thesis is supported; if the company loses share or faces trial failures, the thesis weakens.

Managed-care premium trends and regulatory environment. The parent thesis cites "sound Medicare premium trends" as a structural tailwind. Watch for CMS announcements on Medicare Advantage premium rates, Star ratings (which affect bonus payments), and any additional regulatory actions against UnitedHealth or peers. Deteriorating premium trends or increased regulatory scrutiny would undermine the managed-care leg of the thesis.

Insider buying or selling activity at UnitedHealth, J&J, and Merck. The Berkshire and Tepper exits are now on the record. Watch for any insider purchases by management at these companies, which would signal confidence in valuations and near-term prospects. Conversely, additional insider selling would reinforce the thesis's vulnerability.

Related Arbora context

This thesis is explicitly distinct from the GLP-1 obesity drug coverage thesis (concept-glp1-obesity-drug-coverage), which focuses on CVS Caremark's coverage expansion and LLY/NVO upside. The managed-care aging-demographics thesis is also separate from the large-cap pharma value recovery thesis (concept-pfizer-largecap-pharma-value-recovery), which emphasizes Pfizer's valuation recovery and AbbVie's cash flow generation. The AbbVie M&A thesis (concept-abbvie-largecap-pharma-ma-pipeline-build) highlights pipeline-building through acquisition, which is complementary to Merck's organic pipeline expansion. The healthcare rotation thesis (concept-healthcare-rotation-ai-selloff-hedge) notes that healthcare stocks have gained traction as a defensive alternative during AI selloffs, which may provide near-term support for the names in this thesis but is distinct from the structural aging-demographics narrative.

Sources

This article is research notes, not financial advice.